SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
8-K	Sep 21, 2026	Sep 21, 2026	View filing
4	Sep 16, 2026	Sep 16, 2026	View filing
4	Sep 10, 2026	Sep 10, 2026	View filing
4	Sep 2, 2026	Sep 2, 2026	View filing
4	Aug 18, 2026	Aug 18, 2026	View filing
4	Aug 18, 2026	Aug 18, 2026	View filing
4	Aug 18, 2026	Aug 18, 2026	View filing
SC 13G	Aug 7, 2026	Aug 7, 2026	View filing
4	Aug 6, 2026	Aug 6, 2026	View filing
10-Q	Aug 5, 2026	Aug 5, 2026	View filing
8-K	Aug 5, 2026	Aug 5, 2026	View filing
SC 13G	Jul 31, 2026	Jul 31, 2026	View filing
SC 13G	Jul 31, 2026	Jul 31, 2026	View filing
SC 13G/A	Jul 29, 2026	Jul 29, 2026	View filing
4	Jul 9, 2026	Jul 9, 2026	View filing
4	Jul 2, 2026	Jul 2, 2026	View filing
4	Jul 2, 2026	Jul 2, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
8-K	Jun 18, 2026	Jun 18, 2026	View filing
4	Jun 17, 2026	Jun 17, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 4, 2026	Jun 4, 2026	View filing
4	Jun 4, 2026	Jun 4, 2026	View filing

About Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.

Salt Lake City, UT

600 employees

www.recursion.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Najat Khan

View full financials